The author argues Cipla's exclusive India partnership with Eli Lilly for tirzepatide is underpriced and could make Cipla India's biggest pharma stock within 10 years.
CIPLA.NS — LONG Cipla is the exclusive India partner for Eli Lilly's blockbuster GLP-1 drug tirzepatide, which is scaling faster than any drug in history and addresses large under-penetrated obesity and diabetes markets. The author believes Cipla is plugged into this megatrend without R&D risk and will likely manufacture tirzepatide in India, with patent protection until 2036. This partnership is seen as a multi-year growth driver that the market is underpricing, potentially making Cipla the biggest pharma stock in India over the next 10 years.
I think Cipla can be the biggest pharma stock in India in the next 10 years just off the back off this partnership
This Reddit post, published January 24, 2026, features u/Heartyprofitcalm discussing CIPLA.NS. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Heartyprofitcalm · Tickers: CIPLA.NS